Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | APEX1 | P27695 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3669220 | 0.98 | APEX1 (0.65) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL4074768 | 0.87 | TAAR1 (0.80) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL27577466 | 0.84 | ABAT (0.46) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL27718584 | 0.82 | ABAT (0.44) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL7150334 | 0.82 | TAAR1 (0.59) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL9639314 | 0.82 | TAAR1 (0.59) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL27404752 | 0.82 | ABAT (0.44) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL7146297 | 0.82 | TAAR1 (0.59) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL6612632 | 0.82 | LMNA (0.56) | TAAR1NFKB1TSHRHIF1AHTR3A | |
| SCHEMBL27543042 | 0.82 | ABAT (0.44) | TAAR1NFKB1TSHRHIF1AHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734643-A | The method that iron catalytic amino alcohol synthesizes pyrrolines with enol | 陕西师范大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-104557757-A | CETP inhibitors | MERCK & CO INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104447603-A | CETP inhibitors | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| CN-102304096-B | CETP inhibitors | MERCK SHARP & DOHME | 2014-12-03 | — | — | CN | disclosed |
| CN-102311401-B | CETP inhibitors | MERCK & CO INC | 2014-12-03 | — | — | CN | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102304096-A | CETP inhibitors | MERCK SHARP & DOHME | 2012-01-04 | — | — | CN | disclosed |
| CN-101500594-A | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | SIRION THERAPEUTICS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | TAAR1 3952/4885NFKB1 2367/4885TSHR 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.